^
Association details:
Biomarker:KRAS G12
Cancer:Colorectal Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P-225 KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

Published date:
07/01/2020
Excerpt:
This small retrospective study shows a positive trend in progression-free survival of first-line bevacizumab-based chemotherapy patients with KRAS mutation in codon 13 versus codon 12.
Secondary therapy:
5-fluorouracil + irinotecan; 5-fluorouracil + oxaliplatin
DOI:
10.1016/j.annonc.2020.04.307